Hemodez-H (Haemodes-N)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substancePotassium Chloride + Calcium Chloride + Magnesium Chloride + Sodium Hydrocarbonate + Sodium Chloride + Povidone-8 Thousand.Potassium Chloride + Calcium Chloride + Magnesium Chloride + Sodium Hydrocarbonate + Sodium Chloride + Povidone-8thousand
Similar drugsTo uncover
  • Hemodez-8000
    solution d / infusion 
    BIOSINTEZ, PAO     Russia
  • Hemodez-H
    solution d / infusion 
    MAKSFARM, OJSC     Russia
  • Hemodez-H
    solution d / infusion 
    MOSFARM, LLC    
  • Hemodez-H
    solution d / infusion 
    ESKOM NPK, OAO     Russia
  • Hemodez-H
    solution d / infusion 
    MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC     Russia
  • Hemodez-H
    solution d / infusion 
    Kursk Biofactory - BIOK, FKP     Russia
  • Hemodez-H
    solution d / infusion 
    RESTER, CJSC     Russia
  • Hemodez-H
    solution d / infusion 
    ELFARMI, LTD.     Russia
  • Hemodez-H
    solution d / infusion 
    PHARMSTANDART-UFIM VITAMIN FACTORY, OJSC     Russia
  • Hemodez-H
    solution d / infusion 
    DALHIMFARM, OJSC     Russia
  • Hemodez-H
    solution d / infusion 
    ATOLL, LLC     Russia
  • Krasgemodez 8000
    solution d / infusion 
    BIOSINTEZ, PAO     Russia
  • Krasgemodez 8000
    solution d / infusion 
    KRASFARMA, JSC     Russia
  • Neohemodes
    solution in / in 
    SYNTHESIS, OJSC     Russia
  • Neohemodes
    solution inwards 
    FIRM MEDPOLIMER, JSC     Russia
    • Dosage form: & nbspsolution for infusions
    Composition:

    Polyvinylpyrrolidone low molecular weight medical 8000 ± 2000 (Povidone) - 60 g, sodium chloride - 5.5 g, potassium chloride - 0.42 g, calcium chloride hexahydrate - 0.50 g, magnesium chloride hexahydrate - 0.005 g, sodium bicarbonate - 0, 23 g, water for injection - up to 1 liter.

    Description:Transparent liquid of light yellow or yellow color.
    Pharmacotherapeutic group:Detoxifying agent
    ATX: & nbsp

    B.05.A.A   Blood plasma preparations and plasma-substituting drugs

    Pharmacodynamics:

    The mechanism of action of Hemodeza-H is due to the ability of low molecular weight polyvinylpyrrolidone to bind toxins circulating in the blood and quickly remove them from the body. Hemodez-H differs from hemodesy by the lower molecular weight of polyvinylpyrrolidone used for its manufacture. The decrease in the molecular weight of the polymer accelerates the excretion of it by the kidneys from the body and improves the detoxification properties of the preparation. It increases renal blood flow, increases glomerular filtration and increases diuresis.

    Pharmacokinetics:Metabolic transformations in the body are not affected. Quickly excreted by the kidneys.
    Indications:

    Shock (post-traumatic, postoperative, burn, hemorrhagic), intoxication (toxic diseases of the gastrointestinal tract: dysentery, dyspepsia, salmonellosis); as a means of detoxification in the postoperative period with peritonitis; liver disease,accompanied by the development of liver failure; intestinal obstruction; thyrotoxicosis; burn disease; acute radiation sickness; sepsis; pneumonia; acute myocardial infarction; hemolytic disease of newborns; intrauterine infection and toxemia of newborns; Toxicosis of pregnant women.

    Contraindications:

    Hypersensitivity, intracranial hypertension, hemorrhagic stroke, heart failure IIB-III stage, conditions after craniocerebral injury,cerebral trauma, cerebral hemorrhage, respiratory failure, severe allergic reactions, thromboembolism, oliguria, anuria, acute nephritis, bronchial asthma, phlebothrombosis.

    Carefully:Not described.
    Pregnancy and lactation:Not described.
    Dosing and Administration:

    Before administration, the solution is warmed to body temperature.

    Hemodez-H is intravenously dripped through a system with a filter at a rate of 40-80 drops per minute. A single dose of Hemodeza-H depends on the age of the patient and the severity of intoxication - for adults 200-500 ml; for children 5-10 ml / kg (the maximum single dose for infants is 50-70 ml, 2.5 ml / kg, for children 2-5 years - 100 ml, for children 5-10 years - 100-150 ml , for children 10-15 years - 200 ml).

    The drug is administered 1-2 times a day for 1-10 days, depending on the severity of intoxication.

    In acute gastrointestinal infections, burn and radiation sickness are administered 1-2 times a day; with hemolytic disease and toxemia of newborns - 2-8 times a day (daily or every other day); with large focal myocardial infarction (on the first day) - 200 ml once, with complications on the second day - 200 ml.

    Side effects:

    With the slow introduction of Haemodesum-H, complications do not usually arise. Introduction with increased speed can cause a drop in blood pressure, tachycardia, difficulty breathing and require introduction vasoconstrictor and cardiac agents, calcium chloride. In some patients, it is possible occurrence of allergic reactions, until the development anaphylactic shock. In these cases, you should immediately stop the infusion, conduct symptomatic therapy (introduce antihistamines, cardiotonic drugs, glucocorticoids, vasopressive drugs).

    Overdose:

    In case of an overdose, the drug should be withdrawn and symptomatic therapy should be performed.

    Interaction:

    When mixed with solutions containing a phosphate ion and a carbonate ion, a precipitate may precipitate.

    Special instructions:

    With extensive burns combined with the introduction of plasma, albumin, gamma-globulin and hemotransfusions.

    Before starting the infusion, the doctor must check the integrity and integrity of the package. The drug should be clear, free of sediment and sediment.

    Effect on the ability to drive transp. cf. and fur:Not described.
    Form release / dosage:

    Solution for infusion.

    Packaging:For 100, 250 and 500 ml in polymer containers. 70, 32 or 20 pieces respectively in a box of cardboard corrugated with 3-5 instructions for use (for hospitals).
    Storage conditions:Store in a place protected from light and inaccessible to children at a temperature of 0 to 20 ° C. Freezing of the drug during transportation (provided the container is not leaking) is not a contraindication to the use of the product. After freezing, the containers in the shipping container must be at room temperature until completely thawed, before shaking, mix the solution in the container with shaking.
    Shelf life:2 years. Do not use after the expiration date.
    Terms of leave from pharmacies:On prescription
    Registration number:P N001138 / 01
    Date of registration:14.03.2008
    Expiration Date:Unlimited
    The owner of the registration certificate:RESTER, CJSC RESTER, CJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp21.03.2017
    Illustrated instructions
      Instructions
      Up